Program
zamtocabtagene autoleucel
Also written as “MB-CART2019.1”, “zamtocabtagene autoleucel (MB-CART2019.1)” and “MB-CART2019.1 Dose level 1”.
Its studies are mostly in Lymphoma, B-Cell · Melanoma · Lymphoma, Large B-Cell, Diffuse · Lupus Nephritis · Multiple Sclerosis, led by Miltenyi Biomedicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Miltenyi Biomedicine | 87 open or running | phase 2since Feb 25, 2021 | Feb 25, 2019 | Dec 31, 2026phase 2 · NCT04792489 |
Also a collaborator on its studies: PPD, Part of Thermo Fisher Scientific and ICON.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 25, 2019First study: phase 1 study in Lymphoma, B-CellFirst studyNCT03870945 · 12 enrolled · Germany
- Feb 25, 2021Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04792489 · 315 planned · United States, Canada
- Jun 11, 2024No phase study in MelanomaNCT06508775 · 40 planned · Germany
- Jul 2, 2024Phase 2 study in Lymphoma, B-CellNCT06508931 · 31 planned · France, Germany, Italy and more
- Nov 26, 2024Phase 1 study in Lupus NephritisNCT06708845 · 48 planned · United States
- Jul 28, 2025Phase 2 study in Multiple SclerosisNCT07178431 · 26 planned · Germany
- Nov 20, 2025Phase 2 study in Dendritic Cell Sarcoma, InterdigitatingNCT07288879 · 31 planned · Japan
- Apr 28, 2026Phase 2 study in Lymphoma, Mantle-CellNCT07569965 · 52 planned
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04792489
- Jan 31, 2027Primary completion: phase 2 study in Dendritic Cell Sarcoma, InterdigitatingNCT07288879
- Jan 2028Primary completion: phase 1 study in Lupus NephritisNCT06708845
- Sep 2029Primary completion: phase 2 study in Lymphoma, Mantle-CellNCT07569965
TargetBeta
“A preparation of autologous CD4/CD8 enriched T-lymphocytes engineered to express pLTG1497, a tandem chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, ”NCIt, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07569965Lymphoma, Mantle-Cell | 2 | Not yet recruiting | Sep 2029 | 52 |
| NCT07288879Dendritic Cell Sarcoma, Interdigitating · Japan | 2 | Recruiting | Jan 31, 2027 | 31 |
| NCT07178431Multiple Sclerosis · Germany | 2 | Recruiting | Aug 16, 2030 | 26 |
| NCT06708845Lupus Nephritis · United States | 1 | Recruiting | Jan 2028 | 48 |
| NCT06508931Lymphoma, B-Cell · France, Germany, Italy and more | 2 | Recruiting | Dec 31, 2029 | 31 |
| NCT06508775Melanoma · Germany | – | Recruiting | Dec 31, 2040 | 40 |
| NCT04792489Lymphoma, Large B-Cell, Diffuse · United States, Canada | 2 | Recruiting | Dec 31, 2026 | 315 |
| NCT03870945Lymphoma, B-Cell · Germany | 1 | Completed | Dec 17, 2020 | 12 |
How it is read
Names in the registry
- “MB-CART2019.1”, 3 entries
- “zamtocabtagene autoleucel (MB-CART2019.1)”, 3 entries
- “zamtocabtagene autoleucel”, 1 entry
- “MB-CART2019.1 Dose level 1”, 1 entry
- “MB-CART2019.1 Dose level 2”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, B-Cell, 2 studies
- Melanoma, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
- Lupus Nephritis, 1 study
- Multiple Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.